|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
depletes B cells
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1997
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Rituximab
|
|
gptkbp:can_be_used_with
|
chemotherapy
|
|
gptkbp:clinical_trial
|
oncology
hematology
rheumatology
Phase III
|
|
gptkbp:contraindication
|
active infections
severe allergic reactions
history of progressive multifocal leukoencephalopathy
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
every 6 months
once a week
every 2 weeks
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rituxan
|
|
gptkbp:indication
|
gptkb:Waldenström's_macroglobulinemia
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis
gptkb:healthcare_organization
gptkb:psychologist
gptkb:pemphigus_vulgaris
autoimmune diseases
|
|
gptkbp:invention
|
gptkb:2016
|
|
gptkbp:is_available_on
|
gptkb:physicist
|
|
gptkbp:is_used_for
|
treatment of rheumatoid arthritis
treatment of chronic lymphocytic leukemia
treatment of non-Hodgkin lymphoma
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:Rituximab
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
B cell depletion
half-life of 19 days
|
|
gptkbp:provides_information_on
|
ASCO guidelines
EULAR guidelines
NCCN guidelines
|
|
gptkbp:research
|
neurology
dermatology
immunology
transplantation medicine
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:progressive_multifocal_leukoencephalopathy
fatigue
headache
nausea
cardiovascular events
infections
infusion reactions
hypersensitivity reactions
tumor lysis syndrome
cytopenias
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
C D20 antigen
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:bfsLayer
|
3
|